Literature DB >> 30640246

Epidemiology and incidence of severe respiratory critical events in ear, nose and throat surgery in children in Europe: A prospective multicentre observational study.

Katalin Virag1, Nada Sabourdin, Mark Thomas, Francis Veyckemans, Walid Habre.   

Abstract

BACKGROUND: Ear, nose and throat (ENT) surgery, the most frequently performed surgical procedure in children, is a strong predictor for peri-operative respiratory complications. However, there is no clear information about peri-operative respiratory severe critical events (SCEs) associated with anaesthesia management of ENT children in Europe.
OBJECTIVE: To characterise the epidemiology and incidence of respiratory SCEs during and following ENT surgery in Europe and to identify the risk factors for their occurrence.
DESIGN: A secondary analysis of the Anaesthesia PRactice In Children Observational Trial, a prospective observational multicentre cohort trial.
SETTING: The study included 261 centres across 33 European countries and took place over a consecutive 2-week recruitment period between April 2014 and January 2015. PATIENTS: We extracted data from 5592 ENT surgical procedures that were performed on 5572 children aged 6.0 (3.6) years (mean (SD)) from the surgical database and compared these with data from 15 952 non-ENT surgical children aged 6.7 (4.8) years. MAIN OUTCOME MEASURES: The primary outcome was the incidence of respiratory SCEs (laryngospasm, bronchospasm and new onset of postoperative stridor). Secondary outcomes were the differences in epidemiology between ENT children and non-ENT surgical children and the risk factors for the occurrence of respiratory SCEs.
RESULTS: The incidence (95% confidence interval) of any respiratory SCE (laryngospasm, bronchospasm and postoperative stridor) was 3.93% (3.46 to 4.48) and was significantly higher than that observed in non-ENT surgical children [2.61% (2.37 to 2.87)], with a relative risk of 1.51 (1.28 to 1.77), P less than 0.0001. Younger age (14% decrease in critical events by increasing year, P < 0.0001), history of snoring, recent upper respiratory tract infection and recent wheezing increased the risk of suffering a SCE by over two-fold (P < 0.0001). There was also some evidence for a positive association with age below 4.6 years and lower surgical volume thresholds (<20 cases/2 weeks).
CONCLUSION: The results of this study provide additional evidence for strong associations between risk factors and respiratory SCEs in children having ENT surgery. These observations may facilitate the implementation of good clinical practice recommendations for ENT patients in Europe. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT01878760.

Entities:  

Mesh:

Year:  2019        PMID: 30640246     DOI: 10.1097/EJA.0000000000000951

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  4 in total

Review 1.  [German S1 guideline: obstructive sleep apnea in the context of tonsil surgery with or without adenoidectomy in children-perioperative management].

Authors:  G Badelt; C Goeters; K Becke-Jakob; T Deitmer; C Eich; C Höhne; B A Stuck; A Wiater
Journal:  HNO       Date:  2020-12-22       Impact factor: 1.284

2.  Postoperative respiratory adverse events in children after endoscopic laryngeal cleft repair.

Authors:  Ronica Yalamanchili; Beth Osterbauer; Christian Hochstim
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-13       Impact factor: 3.236

3.  Safety, efficacy and airway complications of the flexible laryngeal mask airway in functional endoscopic sinus surgery: A retrospective study of 6661 patients.

Authors:  Chunhua Xi; Dongjing Shi; Xu Cui; Guyan Wang
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

4.  Perioperative Respiratory Adverse Events Among Pediatric Surgical Patients in University Hospitals in Northwest Ethiopia; A Prospective Observational Study.

Authors:  Desalegn Muche Wudineh; Yophtahe Woldegerima Berhe; Wubie Birlie Chekol; Habtu Adane; Misganaw Mengie Workie
Journal:  Front Pediatr       Date:  2022-02-11       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.